Note: Beijing Tian-Guang real Biotechnology Co., Ltd. of Paradise Valley invested enterprises
Recently, Connaught Jianhua, day wide real BTK (Orelabrutinib) + CD20 with relapsed / refractory CD20 + B cell lymphoma obtained CDE acquiescence.
Connaught-China (Innocare)
Co-founded by world-renowned structural biologist Prof. Shi Yigong and bio-pharmaceutical industry excellence in corporate management Dr. Cui Jisong. We focused on the treatment of cancer and autoimmune diseases in the field of a class of development of new drugs for Chinese patients with high incidence of lymphoma, liver cancer, bile duct cancer and other solid tumors and rheumatoid arthritis and systemic lupus erythematosus and other autoimmune diseases.
The company product line pipeline:
Treatment of systemic lupus erythematosus and rheumatoid arthritis drug development targeting ICP-022's 'successful' Thirteen Five 'National Key New Drug Creation of special project support.
It is reported, ICP-022 in the lymphoma and mantle cell lymphoma, chronic leukemia after completion of Phase II trial, the application data will be the priority review, approval conditions listed.
Product line except a BTK inhibitor, FGFR inhibitor as well as two, respectively ICP105 and ICP-192.
According to the text, probably counted under valuation:
Sunny Investments Limited (Swiss Investment Company) is the largest shareholder of Novo Cheng Jian Hua. According to microblogging Research_ medicine man -Daniel data, a simple calculation after April Connaught-China valued at about $ 860 million. (For reference only) is currently preparing an IPO.
Tian-Guang real
Beijing Tian-Guang real Biotechnology Co., Ltd. (Beijing Mabworks Biotech Co.Ltd)
In is a clinical-stage biopharmaceutical company, with a leading antibody drug development and industrialization of technological capabilities and formed a perfect technology system.
MIL62 it is rituximab (MabThera) and Alto natalizumab (GA101) of product superiority (me-better). MIL62 is the third generation aCD20 antibody fucose knockout proven effective in vitro pharmacodynamics of rituximab imported products, 100% fucose knockout, better than GA101 only 50% of the knock-out level. November 2015 submitted a clinical application to the CFDA, mainly indicated for chronic lymphocytic leukemia. October 31, 2016 to obtain this document clinical, clinical documents of approval: 2016L09586.
(Reprinted from: Drug newsletters official micro-channel public number)
Partners: Paradise Valley in March 2019 to invest in Beijing Tian-Guang real Biotechnology Co., Ltd. by PE funds.